137 related articles for article (PubMed ID: 38252901)
21. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
[TBL] [Abstract][Full Text] [Related]
22. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
DeMichele A; Cristofanilli M; Brufsky A; Liu X; Mardekian J; McRoy L; Layman RM; Emir B; Torres MA; Rugo HS; Finn RS
Breast Cancer Res; 2021 Mar; 23(1):37. PubMed ID: 33761995
[TBL] [Abstract][Full Text] [Related]
23. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.
Bell T; Crown JP; Lang I; Bhattacharyya H; Zanotti G; Randolph S; Kim S; Huang X; Huang Bartlett C; Finn RS; Slamon D
Curr Med Res Opin; 2016 May; 32(5):959-65. PubMed ID: 26894413
[TBL] [Abstract][Full Text] [Related]
24. AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib
Bardia A; Cortes J; Hurvitz SA; Delaloge S; Iwata H; Shao ZM; Kanagavel D; Cohen P; Liu Q; Cartot-Cotton S; Pelekanou V; O'Shaughnessy J
Ther Adv Med Oncol; 2022; 14():17588359221083956. PubMed ID: 35309087
[TBL] [Abstract][Full Text] [Related]
25. Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate.
Fein L; Lazaretti N; Chuken YL; Benfield JRGR; Mano MS; Lobaton J; Korbenfeld E; Damian F; Lu DR; Mori A; Patyna SJ; Franco S
Clin Drug Investig; 2023 Sep; 43(9):699-706. PubMed ID: 37594640
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Gelmon KA; Cristofanilli M; Rugo HS; DeMichele AM; Joy AA; Castrellon A; Sleckman B; Mori A; Theall KP; Lu DR; Huang X; Bananis E; Finn RS; Slamon DJ
Breast J; 2020 Mar; 26(3):368-375. PubMed ID: 31448513
[TBL] [Abstract][Full Text] [Related]
27. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
Ettl J; Im SA; Ro J; Masuda N; Colleoni M; Schnell P; Bananis E; Lu DR; Cristofanilli M; Rugo HS; Finn RS
Breast Cancer Res; 2020 Mar; 22(1):27. PubMed ID: 32164785
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2.
Gelmon K; Walshe JM; Mahtani R; Joy AA; Karuturi M; Neven P; Lu DR; Kim S; Schnell P; Bananis E; Schwartzberg L
Breast; 2021 Oct; 59():321-326. PubMed ID: 34388698
[TBL] [Abstract][Full Text] [Related]
29. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Zhang P; Zhang Q; Tong Z; Sun T; Li W; Ouyang Q; Hu X; Cheng Y; Yan M; Pan Y; Teng Y; Yan X; Wang Y; Xie W; Zeng X; Wang X; Hu C; Geng C; Zhang H; Li W; Wu X; Zhong J; Xu J; Shi Y; Wei W; Bayaxi N; Zhu X; Xu B
Lancet Oncol; 2023 Jun; 24(6):646-657. PubMed ID: 37182538
[TBL] [Abstract][Full Text] [Related]
30. Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India.
Loi S; Karapetis CS; McCarthy N; Oakman C; Redfern A; White M; Khasraw M; Doval DC; Gore V; Alam M; Binko J; Lu DR; Kim S; Boyle F
Asia Pac J Clin Oncol; 2022 Dec; 18(6):560-569. PubMed ID: 34908235
[TBL] [Abstract][Full Text] [Related]
31. Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer.
Rugo HS; Liu X; Li B; McRoy L; Layman RM; Brufsky A
Breast; 2023 Jun; 69():375-381. PubMed ID: 37080011
[TBL] [Abstract][Full Text] [Related]
32. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
33. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
Rugo HS; Diéras V; Gelmon KA; Finn RS; Slamon DJ; Martin M; Neven P; Shparyk Y; Mori A; Lu DR; Bhattacharyya H; Bartlett CHUANG; Iyer S; Johnston S; Ettl J; Harbeck N
Ann Oncol; 2018 Apr; 29(4):888-894. PubMed ID: 29360932
[TBL] [Abstract][Full Text] [Related]
34. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of ribociclib plus letrozole
Buehler AM; Castilho G; Dionne PA; Stefani S
Ther Adv Med Oncol; 2021; 13():17588359211000593. PubMed ID: 33948121
[TBL] [Abstract][Full Text] [Related]
36. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Hart L; Campone M; Petrakova K; Winer EP; Janni W; Conte P; Cameron DA; André F; Arteaga CL; Zarate JP; Chakravartty A; Taran T; Le Gac F; Serra P; O'Shaughnessy J
N Engl J Med; 2022 Mar; 386(10):942-950. PubMed ID: 35263519
[TBL] [Abstract][Full Text] [Related]
37. Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole.
Takahashi M; Osako T; Yasojima H; Inoue K; Kawashima M; Maeda H; Ichikawa A; Muramatsu Y; Masuda N
Breast Cancer; 2024 Jan; 31(1):53-62. PubMed ID: 37882974
[TBL] [Abstract][Full Text] [Related]
38. Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer.
Delaloge S; Dureau S; D'Hondt V; Desmoulins I; Heudel PE; Duhoux FP; Levy C; Lerebours F; Mouret-Reynier MA; Dalenc F; Frenel JS; Jouannaud C; Venat-Bouvet L; Nguyen S; Callens C; Gentien D; Rapinat A; Manduzio H; Vincent-Salomon A; Lemonnier J; Cottu P;
Eur J Cancer; 2022 May; 166():300-308. PubMed ID: 35337692
[TBL] [Abstract][Full Text] [Related]
39. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
Rugo HS; Im SA; Cardoso F; Cortes J; Curigliano G; Musolino A; Pegram MD; Bachelot T; Wright GS; Saura C; Escrivá-de-Romaní S; De Laurentiis M; Schwartz GN; Pluard TJ; Ricci F; Gwin WR; Levy C; Brown-Glaberman U; Ferrero JM; de Boer M; Kim SB; Petráková K; Yardley DA; Freedman O; Jakobsen EH; Gal-Yam EN; Yerushalmi R; Fasching PA; Kaufman PA; Ashley EJ; Perez-Olle R; Hong S; Rosales MK; Gradishar WJ;
J Clin Oncol; 2023 Jan; 41(2):198-205. PubMed ID: 36332179
[No Abstract] [Full Text] [Related]
40. Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom.
Suri G; Chandiwana D; Lee A; Mistry R
J Health Econ Outcomes Res; 2019; 6(2):20-31. PubMed ID: 32685577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
